ArticleThe Journal of clinical investigation2018
Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance.
Article in The Journal of clinical investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 85 citations in OpenAlex.
- Convergent evolution of the N156K mutation in A(H1N1)pdm09 hemagglutinin contributes to antigenic drift and cluster transition.Emerging microbes & infections · 2026Article
- Development and Characterization of Candidate Vaccine Viruses Against High Pathogenicity Avian Influenza A(H5) Viruses for Rapid Pandemic Response.The Journal of infectious diseases · 2026Review
- What Antibody Repertoires See: Structural and Immunogenetic Insights Into Influenza A Virus Hemagglutinin Recognition.Immunological reviews · 2026Review
- Stabilized mosaic hemagglutinin immunogens as novel universal influenza virus vaccines.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Exploring molecular characterization circulating influenza A and B viruses in Tehran, Iran.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Strain Matching of Seasonal Influenza Vaccines and Emergence of Neuraminidase Inhibitor Resistance in China from 2015 to 2025.Vaccines · 2026Article
- Epidemiological and Genomic Characterization of H5 Subtype Avian Influenza Viruses in Jining City, 2024-2025.Pathogens (Basel, Switzerland) · 2026Article
- Article
- Oriented Multivalent Display Drives Consistent Serum Immunodominance to the Ebola Virus Glycoprotein.ACS central science · 2026Article
- Genomic Surveillance and Phylogenetic Analysis of Influenza A(H1N1) pdm09 and A(H3N2) Viruses in Burkina Faso, 2024.Advances in virology · 2026Article
- Screening for next generation vaccines in human immune organoids.ImmunoHorizons · 2025Review
- Immunodominant antibodies against hemagglutinin in ferrets following infection with 2018 to 2019 influenza vaccine strains.NPJ vaccines · 2025Article
- Article
- Remapping the spatial distribution of neutralizing sites and their immunodominance on the capsid of different topotypes of FMDV serotype O by site-directed competitive ELISA for detection of neutralizing antibodies.Microbiology spectrum · 2025Article
- Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Differential antigenic imprinting effects between influenza H1N1 hemagglutinin and neuraminidase in a mouse model.Journal of virology · 2025Article
- Influenza A Virus H7 nanobody recognizes a conserved immunodominant epitope on hemagglutinin head and confers heterosubtypic protection.Nature communications · 2025Article
- Seasonal influenza vaccines: Variability of immune responses to B lineage viruses.Human vaccines & immunotherapeutics · 2024Review
- Preclinical evaluation of a universal inactivated influenza B vaccine based on the mosaic hemagglutinin-approach.NPJ vaccines · 2024Article
- An epidemiologic surveillance study based on wastewater and respiratory specimens reveals influenza a virus prevalence and mutations in Taiyuan, China during 2023-2024.BMC infectious diseases · 2024Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
Hemagglutination inhibition (HI) titers are a major correlate of protection for influenza-related illness. The influenza virus hemagglutinin possesses antigenic sites that are the targets of HI active antibodies. Here, a panel of mutant viruses each lacking a classically defined antigenic site was created to compare the species-specific immunodominance of the antigenic sites in a clinically relevant hemagglutinin. HI active antibodies of antisera from influenza virus-infected mice targeted sites Sb and Ca2. HI active antibodies of guinea pigs were not directed against any specific antigenic site, although trends were observed toward Sb, Ca2, and Sa. HI titers of antisera from infected ferrets were significantly affected by site Sa. HI active antibodies of adult humans followed yet another immunodominance pattern, in which sites Sb and Sa were immunodominant. When comparing the HI profiles among different species by antigenic cartography, animals and humans grouped separately. This study provides characterizations of the antibody-mediated immune responses against the head domain of a recent H1 hemagglutinin in animals and humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.